ribG

Abstract: The invention provides ribG polypeptides and polynucleotides encoding ribG polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing ribG polypeptides to screen for antibacterial compounds.

Description: ribG RELATED APPLICATIONS This application claims benefit of US Patent Application. Number 08/978.456 filed November 25 1997 FIELD OF THE INVENTION This invention relates to newly identified polynucleotides and polypeptides. and their production and uses, as well as their vanants, agonists and antagonists, and their uses In particular. tire invention relates to novel polvnucleotides and polypeptides of the riboflavrn specific deaminase family, hereinafter referred to as "nbG" BACKGROUND OF THE INVENTION It is particularly preferred to employ Staphylococcal genes and gene products as targets for the development of antibiotics The Staphylococci make up a medically important genera of microbes They are known to produce two types of disease, invasive and toxigemc Invasive infections are charactenzed generally by abscess formation effecting both skin surfaces and deep tissues S aureus is the second leading cause of bacteremia in cancer patients Osteomyelitis, septic arthntis, septic thrombophlebitis and acute bactenal endocarditis are also relatively common There are at least three clinical conditions resulting from the toxigemc properties of Staphylococci The manifestation of these diseases result from the actions of exotoxins as opposed to tissue invasion and bacteremia These conditions include Staphylococcal food poisoning, scalded skin syndrome and toxic shock syndrome Riboflavm (vitamin B2) is a member of the B complex of vitamins which function as coenzymes in metabolic reactions Riboflavm has two coenzyme forms, flavin mononucleotide (FMN) and flavin ademne dinucleotide (FAD) which act in oxidation-reduction reactions such as the cytochrome system of electron transport and the oxidative degradation of pyruvate. fatty acids and ammo acids The first committed step in the biosynthesis of riboflavm is the opemng of the imidazole ring of GTP In the presence of 3 H2O .and Mg ++ . the C-8 of GTP is released as formate accompanied by the release of pyrophosphate by the action of GTP cyclohyrolase II (GCH2, EC 3 5 4 25) This enzyme function is encoded by nbA m bacteria and ribl in yeast species Through a series of steps, involving 3J-dιhydroxy-2-butanone 4 phosphate synthase (nbA), 6,7-dιmethyl-8-rιbιtyllumazme synthase (nbH), riboflavm synthase (ribB), pyr midine deaminase and pyrrmidine reductase (nbG). enzymes encoded by genes withm the riboflavm biosynthesis operon, riboflavm is formed Because the genes required for riboflavm biosynthesis are present in many pathogenic microorganisms, and since riboflavm biosynthesis has shown to be required for virulence in the swine pathogen Actinobacillus pleuropneumomae (Fuller. TE. et al (1996) A riboflavm auxotroph of Actinobacillus pleuropneumomae is attenuated m swine Infect Immun 64 4659-4664), these gene products represent broad spectrum antibacterial as well as antifungal targets The frequency of Staphylococcus aureus infections has nsen dramatically in the past few decades This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems It is no longer uncommon to isolate Staphylococcus aureus strains which are resistant to some or all of the standard antibiotics This phenomenon has created a demand for both new .anti-microbial agents, vaccines, and diagnostic tests for this organism Clearly, there exists a need for factors, such as the nbG embodiments of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction .and disease Certain of the polypeptides of the invention possess ammo acid sequence homology to a known Bacillus subti s nbG protein SUMMARY OF THE INVENTION It is an object of the invention to provide polypeptides that have been identified as novel nbG polypeptides by homology between the ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4] and a known ammo acid sequence or sequences of other proteins such as Bacillus subtihs nbG protein It is a further object of the invention to provide polynucleotides that encode nbG polypeptides. particularly polynucleotides that encode the polypeptide herem designated nbG In a particularly preferred embodiment of the invention the polynucleotide compnses a region encodmg nbG polypeptides compnsmg a sequence set out in Table 1 [SEQ ID NO 1 or 3] which includes a fxill length gene, or a variant thereof In another particularly preferred embodiment of the invention there is a novel nbG protem from Staphylococcus aureus comprising the ammo acid sequence of Table 1 [SEQ ID NO 2 or 4]. or a variant thereof In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encodmg a mature polypeptide expressible by the Staphylococcus aureus WCUH29 on deposit strain, which nucleic acid is contained in the deposited strain A further aspect of the mvention there are provided isolated nucleic acid molecules encodmg nbG. particularly Staphylococcus aureus nbG. including mRNAs. cDNAs, genomic DNAs Further embodiments of the mvention include biologically, diagnostically, prophylactically. clinically or therapeutically useful variants thereof, and compositions compnsmg the same In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization Among the particularly preferred embodiments of the mvention are naturally occurring allelic vanants of nbG and polypeptides encoded thereby Another .aspect of the mvention there are provided novel polypeptides of Staphylococcus aureus referred to herem as nbG as well as biologically, diagnostically. prophylactically. clinically or therapeutically useful vanants thereof, and compositions compnsmg the same Among the particularly preferred embodiments of the mvention are vanants of nbG polypeptide encoded by naturally occurring alleles of the nbG gene In a preferred embodiment of the mvention there are provided methods for producmg the aforementioned nbG polypeptides In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides. useful as antibacterial agents, including, for example, antibodies In accordance with certain preferred embodiments of the mvention, there are provided products, compositions and methods for .assessing nbG expression, treating disease, assaying genetic vanation. and administering a nbG polypeptide or polynucleotide to an organism to raise an lmmunological response against a bactena, especially a Staphylococcus aureus bactena In accordance with certain preferred embodiments of this and other aspects of the mvention there are provided polynucleotides that hybndize to nbG polynucleotide sequences, particularly under stringent conditions In certain preferred embodiments of the mvention there are provided antibodies against nbG polypeptides In other embodiments of the mvention there are provided methods for ldentrfying compounds which bmd to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the mvention compnsmg contacting a polypeptide or polynucleotide of the mvention with a compound to be screened under conditions to permit bmdmg to or other mteraction between the compound and the polypeptide or polynucleotide to assess the bmdmg to or other mteraction with the compound, such bmdmg or mteraction being associated with a second component capable of providing a detectable signal m response to the bmdmg or mteraction of the polypeptide or polynucleotide with the compound, and determining whether the compound bmds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detectmg the presence or absence of a signal generated from the bmdmg or mteraction of the compound with the polypeptide or polynucleotide In accordance with yet another aspect of the mvention, there are provided nbG agonists and antagonists, preferably bactenostatic or bactenocidal agonists and antagonists In a further aspect of the mvention there are provided compositions compnsmg a nbG polynucleotide or a nbG polypeptide for administration to a cell or to a multicellular organism Various changes and modifications within the spmt and scope of the disclosed mvention will become readily apparent to those skilled m the art from reading the following descnptions and from reading the other parts of the present disclosure DESCRIPTION OF THE INVENTION The mvention relates to novel nbG polypeptides and polynucleotides as descnbed m greater detail below In particular, the mvention relates to polypeptides and polynucleotides of a novel nbG of Staphylococcus aureus. which is related by ammo acid sequence homology to Bacillus subtihs nbG polypeptide The mvention relates especially to nbG having the nucleotide and ammo acid sequences set out m Table 1 as SEQ ID NO 1 and SEQ ID NO 2 respectivelynbG TABLE 1 ribG Polynucleotide and Polypeptide Sequences (A) Sequences from Staphylococcus aureus ribG polynucleotide sequence [SEQ ID NO: 1]. 5 ' - ATGGATTATGCGATTCAACTTGCAAATATGGTACAAGGTCAAACAGGTGTTAATCCACCCGTTGGCGCT GTTGTAGTTAATGAAGGTAGGATTGTTGGTATTGGTGCACACTTGAGAAAAGGTGACAAGCATGCGGAG GTTCAAGCACTTGATATGGCACAACAAAATGCTGAAGGTGCGACGATTTATATTACGTTAGAGCCATGT AGTCATTTTGGTTCAACACCACCCTGTGTTAACAAAATTATTGATTGTAAGATAGCAAAAGTAGTATAC GCAACAAAAGACAATTCGTTAGACACACATGGTGATGAGACGTTACGGGCTCACGGTATTGAGGTTGAA TGCGTTGATGATGAACGGGCATCACAATTATACCAAGACTTTTTTAAAGCAAAAGCAAAGCAACTGCCA CAAATTACAGTGAAAGTATCTGCAAGTTTAGATGGTAAACAAGCGAATGATAATGGACAAAGTCAATGG ATTACTAACAAAGAGGTTAAACAAGATGTCTATAAGTTAAGACATCGACACGACGCAGTGTTAACTGGA AGACGTAC AGTTGAATTAGATGATCCACAATATACTACACGTATTCAAGATGGAAAAAACCCTATAAAAGTAATATT GTCTAAGTCTGGGAATATTCATTTTAATCAGCAAATTTATCAAGATGAATCAACACCAATTTGGATATA TACTGAAAATCCAAATTTAACAAGCAATCAAACACATATTGAAATTATTTACTTGAAGTCTTGTGATTT AACAACAATTCTTCACAATTTATATAAAAGAGGAGTTGGAACTTTGCTAGTCGAGGCAGGTCCAACCAC TACTTCAGAATTCTCCATCTATTATATAGATGAATTTATTCTCTATTATGCCCCGAAATTAATTGGCGG ATCTGGAAATTATCAATTTTATCAAACAAATGATGTGATTGAGATA.CCAGATGCGAACCAATTTGAAAT TGTTCATTCCGAGTTATTAAATCAAAATGTTAAATTAACTTTACGAAAGAAGTGA-3' (B) Staphylococcus aureus ribG polypeptide sequence deduced from the polynucleotide sequence in this table [SEQ ID NO:2]. NH 2 - MDYAIQlj/^Nl^rVQGQTGVNPPVGAVWNEGRIVGI GAHLRKGDKHAEVQALDMAQQNAEGATIYITLEPC SHFGSTPPCVNKI I DCKIAKWYATKDNSLDTHGDETLRAHGI EVECVDDERASQLYQDFFKAKAKQLP QITV VSASLDGKQANDNGQSQWITNKEVKQDVYKLRHRHDAVLTGRRTVELDDPQYTTRIQDGKNPI K VILSKSGNIHFNQQIYQDESTPI IYTENPNLTSNQTHIEI IYLKSCDLTTILHNLYKRGVGTL VEAG PTTTSEFS IYYI DEFILYYAPKLI GGSGNYQFYQTNDVI EI PDANQFEIVHSELLNQNVKLTLRKK- COOH (C) Polynucleotide sequences comprising Staphylococcus aureus ribG ORF sequence [SEQ ID NOJ], 5 ' - AANCACCAATCCNATTGGGAGGNAATCCAAATCAATNCCCGGANNCCCAATCCAAGTTAATTAAGTCCA AGGTTTTGGAACATTACCAAATATGATTCCGATGAGGTCAAATGNCAANCGGTGTTAATAAACTACGAA ATGNTGTGNAAATGATAGTAGANCAAGTTGCGCATACAGTNTCTCNATTATATGATGCTTTAGAATCGA ATGAGCAACAACAGCGCAGTTACAATCAATAATTTGTAACTAGAAGATAATAAAGAGAACGCTCTATAG AGACGAATTGAAGGTTTGATTTTAATGTCTGTTAGTAAGAATCATATCAATGAGATGCCTATAGTACTC AGATTATATTAAATTAAAACCGTCATTAATTGTTTTTTTAGAAAACATATAGTATCATTTTAAATGTAG TTGACATACTACGTACTCAAATAATCTATAACAATTTCATATATAATTCTTTCGGGGCAGGGTGAAATT CCCAACCGGCAGTAAATAAAGCCTGCGACCTGCTAATATGTTTCATATTAGTGGCTGATCTAGTGAGAT TCTAGAGCCGACAGTTAAAGTCTGGATGGGAGAAAGAATGTTAATTATCGACAAAGATAATGTAGCGTA TTTGTAAAAATGTGTACAAATAGGCTTATTTAACGATAA ATTTTTCTCCTTTGCATCTTAATTCATGATGTGAGGATTTTTTGTTTATAGAGGTGATCATTTGAGTCA ATTTATGGATTATGCGATTCAACTTCCAAATATGGTACAAGGTCANACAGGTGTTAATCCACCCGTTGG CGCTGTTGTAGTTAATGAAGGTAGGATTGTTGGTATTGGTGCACACTTGAGAAAAGGTGACAAGCATGC GGAGGTTCAAGCACTTGATATGGCACAACANAATGCTGAAGGTGCGACGATTTATATTACGTTAGAGCC ATGTAGTCATTTTGGTTCAACACCACCCTGTGTTAACAAAATTATTGATTGTAAGATAGCANAAGTAGT ATTACNCAACANAAGACAATTCCGTTAGACACACATGGGTGATGAGACGTTACGGGGCTCCACGGTATT TGAGGGTTGAATTGCGTTGGATGATGAACGGGCATCACAATTATACCAAAGACTTTTTTTAAAGCAAAA AGCAAAGCAACTTGCCACAAAATTACAGTGAAAGTNTCTTGAAAGTTTAGATGGGTAAACAAAGCGAAT TGATAATGGACAAAGTCAATGGATTACTAACAAAGAGGTTAAACAAGATGTCTATAG-3 ' (D) Staphylococcus aureus nbG polypeptide sequence deduced from the polynucleotide ORF sequence in this table [SEQ ID NO 4] NH ^ - MDYAI QLPNl^TVQGXTGVNPPVGAλ/VVNEGRIVGI GAHLRKGDKHAEVQALDMAQXNAEGATIYITLEPC SHFGSTPPCVNKI IDCKIAXWLXNXRQFR -COOH Deposited materials A deposit containing a Staphylococcus aureus WCUH 29 stram has been deposited with the National Collections of Industnal and Marine Bactena Ltd (herem "NCIMB"), 23 St Machar Dnve, Aberdeen AB2 1RY, Scotland on 11 September 1995 and assigned NCIMB Deposit No 40771. and referred to as Staphylococcus aureus WCUH29 on deposit The Staphylococcus aureus stram deposit is referred to herem as "the deposited stram" or as "the DNA of the deposited stram " The deposited stram contains the full length nbG gene The sequence of the polynucleotides contained in the deposited stram, as well as the ammo acid sequence of the polypeptide encoded thereby, are controlling m the event of any conflict with anv descnption of sequences herem The deposit of the deposited stram has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure The stram will be irrevocably and without restnction or condition released to the public upon the issuance of a patent The deposited stram is provided merely as convenience to those of skill m the art and is not an admission that a deposit is required for enablement, such as that required under 35 U S C §112 A license may be required to make, use or sell the deposited stram, and compounds denved therefrom, and no such license is hereby granted One aspect of the mvention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the Staphylococcus aureus WCUH 29 .strain contained m the deposited stram Further provided by the mvention are nbG nucleotide sequences of the DNA m the deposited strain and ammo acid sequences encoded thereby Also provided by the mvention are nbG polypeptide sequences isolated from the deposited stram and ammo acid sequences denved therefrom Polypeptides The polypeptides of the mvention mclude a polypeptide of Table 1 [SEQ ID NO 2 or 4] (m particular the mature polypeptide) as well as polypeptides and fragments, particularly those which have the biological activity of nbG. and also those which have at least 70% identity to a polypeptide of Table 1 [SEQ ID NO 1 or 3]or the relevant portion, preferably at least 80% identity to a polypeptide of Table 1 [SEQ ID NO 2 or 4and more preferably at least 90% simiknty (more preferably at least 90% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and still more preferably at least 95% srmilanty (still more preferably at least 95% identity) to a polypeptide of Table 1 [SEQ ID NO 2 or 4] and also mclude portions of such polypeptides with such portion of the polypeptide generally containing at least 30 ammo acids and more preferably at least 50 ammo acids The mvention also mcludes polypeptides of the formula X-(Rι ) m -(R 2 )-(R 3 ) n -Y wherein, at the ammo terminus, X is hydrogen, and at the carboxJ terminus. Y is hydrogen or a metal, R j and R3 are any ammo acid residue, m is an mteger between 1 and 1000 or zero, n is an mteger between 1 and 1000 or zero, and R 2 is an ammo acid sequence of the mvention. particularly an ammo acid sequence selected from Table 1 In the formula above R 2 is onented so that its ammo terminal residue is at the left, bound to Ri and its carboxy terminal residue is at the nght. bound to R3 Any stretch of ammo acid residues denoted by either R group, where m and or n is greater than 1. may be either a heteropolymer or a homopolymer. preferably a heteropolymer A fragment is a vanant polypeptide having an ammo acid sequence that entireh is the same •as part but not all of the ammo acid sequence of the aforementioned polypeptides As with nbG polypeptides fragments may be "free-standing," or compnsed within a larger polypeptide of which they form a part or region, most preferably as a smgle contmuous region, a smgle larger polypeptide Preferred fragments mclude, for example, truncation polypeptides having a portion of an ammo acid sequence of Table 1 [SEQ ID NO 2 or 4]. or of vanants thereof, such as a contmuous senes of residues that mcludes the ammo terminus, or a contmuous senes of residues that includes the carboxJ terminus Degradation forms of the polypeptides of the mvention m a host cell, particularl} a Staphylococcus aureus, are also preferred Further preferred are fragments characterized by structural or functional attributes such as fragments that compnse alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-foπnmg regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hvdrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate bmdmg region- and high antigemc mdex regions a lso preferred are biologically active fragments winch are those fragments that mediate activities of nbG, including those with a similar activity or an improved activity, or with a decreased undesirable activity Also mcluded are those fragments that are antigemc or immunogemc m an animal, especially m a human Particularly prefened are fragments compnsmg receptors or domains of enzymes that confer a function essential for viability of Staphylococcus aureus or the ability to initiate, or maintain cause disease in an individual, particularly a human Vanants that are fragments of the polypeptides of the mvention may be employed for producmg the correspondmg full-length polypeptide by peptide synthesis, therefore, these vanants may be employed as intermediates for producmg the full-length polypeptides of the mvention In addition to the standard smgle and triple letter representations for ammo acids, the term "X" or "Xaa" may also be used in describing certain polypeptides of the invention "X" and "Xaa" mean that any of the twenty naturally occurmg amino acids may appear at such a designated position m the polypeptide sequence Polynucleotides Another aspect of the mvention relates to isolated polynucleotides, including the full length gene, that encode the nbG polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] and polynucleotides closely related thereto and vanants thereof Using the information provided herem, such as a polynucleotide sequence set out m Table 1 [SEQ ID NO 1 or 3]. a polynucleotide of the mvention encodmg nbG polypeptide may be obtained usmg standard cloning and screening methods, such as those for cloning and sequencmg chromosomal DNA fragments from bactena usmg Staphylococcus aureus WCUH 29 cells as starting matenal, followed by obtaining a full length clone For example, to obtain a polynucleotide sequence of the mvention, such as a sequence given in Table 1 [SEQ ID NO 1 or 3], typically a library of clones of chromosomal DNA of Staphylococcus aureus WCUH 29 m. E coll or some other suitable host is probed with a radiolabeled ohgonucleotide. preferably a 17-mer or longer, denved from a partial sequence Clones carrying DNA identical to that of the probe can then be distinguished usmg strmgent conditions By sequencmg the individual clones thus identified with sequencmg primers designed from the origmal sequence it is then possible to extend the sequence m both directions to determine the full gene sequence Conveniently, such sequencmg is performed usmg denatured double stranded DNA prepared from a plasmid clone Suitable techniques are described by Maniatis, T , Fritsch, E F and Sambrook et al , MOLECULAR CLONING A LABORATORY MANUAL. 2nd Ed , Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York (1989) (see m particular Screen g By Hybridization 1 90 and Sequencmg Denatured Double-Stranded DNA Templates 13 70) Illustrative of the mvention, the polynucleotide set out m Table 1 [SEQ ID NO 1 or 3] was discovered in a DNA library denved from Staphylococcus aureus WCUH 29 The DNA sequence set out m Table 1 [SEQ ID NO 1 or 3J contains an open reading frame encodmg a protem having about the number of ammo acid residues set forth m Table 1 [SEQ ID NO 2 or 4] with a deduced molecular weight that can be calculated usmg ammo acid residue molecular weight values well known in the art The polynucleotide of SEQ ID NO 1. between nucleotide number 1 and the stop codon which begms at nucleotide number 1027 of SEQ ID NO 1. encodes the polypeptide of SEQ ID NO 2 RibG of the mvention is structurally related to other proteins of the nboflavm specific deaminase family The mvention provides a polynucleotide sequence identical over its entire length to a coding sequence m Table 1 [SEQ ID NO 1 or 3] Also provided by the indention is the coding sequence for the mature polypeptide or a fragment thereof, by itself as well as the coding sequence for the mature polypeptide or a fragment m reading frame with other coding sequence, such as those encoding a leader or secretory sequence, a pre-, or pro- or prepro- protem sequence The polynucleotide may also contain non-coding sequences, including for example, but not limited to non-coding 5 and 3' sequences, such as the transcnbed. non-translated sequences, termination signals, nbosome bmdmg sites, sequences that stabilize niRNA. lntrons. polyadenylation signals, and additional coding sequence which encode additional ammo acids For example, a marker sequence that facilitates punfication of the fused polypeptide can be encoded In certain embodiments of the mvention. the marker sequence is a hexa-histidine peptide. as provided m the pQE vector (Qiagen. Inc ) and descnbed in Gentz et al , Proc Natl Acad Sci , USA 86 821-824 (1989), or an HA tag (Wilson et al , Cell 37 767 (1984) Polynucleotides of the mvention also mclude, but are not limited to, polynucleotides compnsmg a structural gene and its naturally associated sequences that control gene expression A preferred embodiment of the mvention is a polynucleotide of compnsmg nucleotide 1 to the nucleotide immediately upstream of or including nucleotide 1027 set forth m SEQ ID NO 1 of Table 1. both of which encode the nbG polypeptide The mvention also mcludes polynucleotides of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherem. at the 5' end of the molecule. X is hydrogen, and at the 3' end of the molecule. Y is hydrogen or a metal. Ri and R3 is any nucleic acid residue, m is an mteger between 1 and 3000 or zero . n is an mteger between 1 and 3000 or zero, and R 2 is a nucleic acid sequence of the mvention. particular.} a nucleic acid sequence selected from Table 1 In the polynucleotide formula above R 2 is onented so that its 5' end residue is at the left, bound to Ri and its 3 1 end residue is at the nght, bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer. preferably a heteropolymer In a preferred embodiment m and/or n is an mteger between 1 and 1000. It is most prefened that the polynucleotides of the mventions are denved from Staphylococcus aureus. however, they may preferably be obtained from organisms of the same taxonomic genus They may also be obtained, for example, from org-amsims of the same taxonomic family or order The term "polynucleotide encodmg a polypeptide" as used herem encompasses polynucleotides that mclude a sequence encodmg a polypeptide of the mvention, particularly a bactenal polypeptide and more particularly a polypeptide of the Staphylococcus aureus nbG having an ammo acid sequence set out in Table 1 [SEQ ID NO 2 or 4] The term also encompasses polynucleotides that mclude a smgle contmuous region or discontinuous regions encodmg the polypeptide (for example, mterrupted by mtegrated phage or an insertion sequence or editmg) together with additional regions, that also may contain coding and/or non-coding sequences The mvention further relates to vanants of the polynucleotides descnbed herem that encode for vanants of the polypeptide having a deduced ammo acid sequence of Table 1 [SEQ ID NO 2 or 4] Vanants that are fragments of the polynucleotides of the mvention may be used to synthesize full- length polynucleotides of the mvention Further particularly preferred embodiments are polynucleotides encodmg nbG vanants. that have the ammo acid sequence of nbG polypeptide of Table 1 [SEQ ID NO 2 or 4] in which several, a few. 5 to 10, 1 to 5. 1 to 3, 2, 1 or no am o acid residues are substituted, deleted or added, in any combination Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of nbG Further preferred embodiments of the mvention are polynucleotides that are at least 70% identical over their entire length to a polynucleotide encodmg nbG polypeptide having an ammo acid sequence set out m Table 1 [SEQ ID NO 2 or 4]. and polynucleotides that are complementaπ to such polynucleotides Alternatively, most higlily prefened are polynucleotides that compnse a region that is at least 80% identical over its entire length to a polynucleotide encodmg nbG polypeptide and polynucleotides complementary thereto In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly prefened, and among these particularly prefened polynucleotides, those with at least 95% are especially preferred Furthermore, those with at least 97% are highly prefened among those with at least 95%. and among these those with at least 98% and at least 99% are particularly highly prefened, with at least 99% bemg the more prefened Preferred embodiments are polynucleotides that encode polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded b\ a DNA of Table 1 [SEQ ID NO 1 or 3] The mvention further relates to polynucleotides that hybndrze to the herem above-descnbed sequences In this regard, the mvention especially relates to polynucleotides that hybndize under stringent conditions to the herem above-descnbed polynucleotides As herem used, the terms "strmgent conditions" and "strmgent hybndization conditions" mean hybπdization will occur if there is at least 95% and preferably at least 97% identity between the sequences An example of stnngent hybridization conditions is overnight incubation at 42°C in a solution compnsmg 50% formamide, 5x SSC (150mM NaCl, 15mM tnsodium citrate). 50 mM sodium phosphate (pH7 6), 5x Denhardt's solution. 10% dextran sulfate. and 20 micrograms/ml denatured, sheared salmon sperm DNA. followed by washing the hybridization support in 0 lx SSC at about 65°C Hybridization and wash conditions are well known -and exemplified in Sambrook, et al , Molecular Cloning A Laboratory Manual, Second Edition, Cold Sprmg Harbor, N Y , (1989), particularly Chapter 11 therein The mvention also provides a polynucleotide consistmg essentially of a polynucleotide sequence obtainable by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO 1 under stringent hybridization conditions with a probe havmg the sequence of said polynucleotide sequence set forth m SEQ ID NO 1 or a fragment thereof, and isolating said DNA sequence Fragments useful for obtaining such a polynucleotide mclude, for example, probes and primers described elsewhere herein As discussed additionally herem regarding polynucleotide assays of the mvention. for instance, polynucleotides of the mvention as discussed above, may be used as a hybndization probe for RNA. cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encodmg nbG and to isolate cDNA and genomic clones of other genes that have a high sequence similanty to the nbG gene Such probes generally will compnse at least 15 bases Preferably, such probes will have at least 30 bases and may have at least 50 bases Particularly prefened probes will have at least 30 bases and will have 50 bases or less For example, the coding region of the nbG gene may be isolated by screening usmg a DNA sequence provided m Table 1 [SEQ ID NO 1 or 3] to synthesize an o gonucleotide probe A labeled ohgonucleotide havmg a sequence complementary to that of a gene of the mvention is then used to screen a library of cDNA. genomic DNA or mRNA to determine which members of the library the probe hybndizes to The polynucleotides and polypeptides of the mvention ma\ be employed, for example, as research reagents and matenals for discovery of treatments of and diagnostics for disease, particularly human disease, as further discussed herem relatmg to polvnucleotide assays Polynucleotides of the invention that are ohgonucleotides derived from the sequences of Table 1 [SEQ ID NOS 1 or 2 or 3 or 4] may be used in the processes herem as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed m bacteria in infected tissue It is recognized that such sequences will also have utility m diagnosis of the stage of infection and type of mfection the pathogen has attained The mvention also provides polynucleotides that may encode a polypeptide that is the mature protem plus additional ammo or carboxyl-termrnal ammo acids, or ammo acids mtenor to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance) Such sequences may play a role m processmg of a protem from precursor to a mature form, may allow protem transport, may lengthen or shorten protem half-life or may facilitate manipulation of a protem for assay or production, among other things As generally is the case in vivo, the additioiral ammo acids may be processed away from the mature protem by cellular enzymes A precursor protem, havmg the mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide When prosequences are removed such inactive precursors gener ly are activated Some or all of the prosequences may be removed before activation Generally, such precursors are called proprotems In addition to the standard A, G, C. T/U representations for nucleic acid bases, the term "N" may also be used in descnbmg certain polynucleotides of the invention "N" means that any of the four DNA or RNA bases may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a base that when taken m combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon m such reading frame In sum, a polynucleotide of the mvention may encode a mature protem, a mature protem plus a leader sequence (which may be refened to as a preprotem). a precursor of a mature protem havmg one or more prosequences that are not the leader sequences of a preprotem. or a preproprotein. which is a precursor to a proprotem. havmg a leader sequence and one or more prosequences. which generally are removed during processmg steps that produce active and mature forms of the polypeptide Vectors, host cells, expression The mvention also relates to vectors that compnse a polvnucleotide or polynucleotides of the mvention. host cells that are genetically engmeered with vectors of the mvention and the production of polypeptides of the mvention by recombmant techniques Cell-free translation systems can also be employed to produce such protems usmg RNAs denved from the DNA constructs of the mvention For recombmant production, host cells can be genetically engmeered to incorporate expression systems or portions thereof or polynucleotides of the mvention Introduction of a polynucleotide mto the host cell can be effected by methods descnbed m many standard laboratory manuals, such as Davis et al , BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook et al . MOLECULAR CLONING A LABORATORY MANUAL, 2nd Ed . Cold Spnng Harbor Laboratory Press. Cold Spnng Harbor, N Y (1989). such as. calcium phosphate transfection. DEAE-dextran mediated transfection. transvection. micro njection, cationic pid- mediated transfection, electroporation. transduction, scrape loading, balhstic introduction and infection Representative examples of appropnate hosts mclude bactenal cells, such as streptococci, staphylococci, enterococci E cob, streptomyces and Bacillus subtihs cells, fungal cells, such as yeast cells and Aspergillus cells, insect cells such as Drosophila S2 .and Spodoptera Sf9 cells, animal cells such as CHO, COS, HeLa. C127. 3T3, BHK. 293 and Bowes melanoma cells, and plant cells A great vanety of expression systems can be used to produce the polypeptides of the mvention Such vectors mclude. among others, chromosomal, episomal and virus-denved vectors, e g . vectors denved from bactenal plasmids, from bactenophage. from transposons. from yeast episomes. from insertion elements, from yeast chromosomal elements, from viruses such as baculovrruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses. and vectors denved from combinations thereof, such as those denved from plasmid and bactenophage genetic elements, such as cosmids and phagemids The expression system constructs may contam control regions that regulate as well as engender expression Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide m a host may be used for expression m this regard The appropnate DNA sequence may be inserted into the expression system by any of a vanety of well-known and routme techmques, such as, for example, those set forth in S-ambrook et αl . MOLECULAR CLONING, A LABORATORY MANUAL, (supra) For secretion of the translated protem mto the lumen of the endoplasmic reticulum. mto the penplasmic space or mto the extracellular environment, appropnate secretion signals may be incorporated mto the expressed polypeptide These signals may be endogenous to the polypeptide or they may be heterologous signals Polypeptides of the mvention can be recovered and purified from recombmant cell cultures by well-known methods including -ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography. phosphocellulose chromatography. hydrophobic mteraction chromatograph * , . affinity chromatography. hydroxylapatite chromatography, and lectm chromatography Most preferably, high performance liquid chromatography is employed for purification Well known techniques for refolding protem may be employed to regenerate active conformation when the polypeptide is denatured during isolation and or punfication Diagnostic Assays This mvention is also related to the use of the nbG polynucleotides of the mvention for use as diagnostic reagents Detection of nbG in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of a disease Eukaryotes (herem also "mdιvιdual(s)"), particularly mammals, and especially humans, particularly those mfected or suspected to be infected with an organism compnsmg the nbG gene may be detected at the nucleic acid level by a vanety of techmques Nucleic acids for diagnosis may be obtained from an infected individual's cells and tissues, such as bone, blood, muscle, cartilage, and skin Genomic DNA may be used directly for detection or may be amplified enzymatically by usmg PCR or other amplification technique pnor to analysis RNA. cDNA and genomic DNA may also be used in the same ways Usmg amplification, characterization of the species -and stram of prokaryote present m an individual, may be made bv an analysis of the genotype of the prokaryote gene Deletions and insertions can be detected by a change m size of the amplified product m companson to the genotype of a reference sequence Point mutations can be identified by hybndizing -amplified DNA to labeled nbG polynucleotide sequences Perfectly matched sequences can be distmguished from mismatched duplexes by RNase digestion or by differences m meltmg temperatures DNA sequence differences may also be detected by alterations in the electrophoretic mobility of the DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencmg See. e g . Myers et al . Science, 230 1242 (1985) Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase and SI protection or a chemical cleavage method See. e g . Cotton et al . Proc Natl Acad Sci , USA, 85 4397-4401 (1985) Cells carrying mutations or polymorphisms in the gene of the mvention may also be detected at the DNA level by a vanety of techmques. to allow for serotyping. for ex unple For example. RT- PCR can be used to detect mutations It is particularly preferred to used RT-PCR m conjunction with automated detection systems, such as, for example. GeneScan RNA, cDNA or genomic DNA may also be used for the same purpose. PCR or RT-PCR As an example, PCR primers complementary to a nucleic acid encodmg nbG can be used to identify and analyze mutations Examples of representative primers are shown below m Table 2 Table 2 Primers for amplification of ribG polynucleotides SEQ ID NO PRIMER SEQUENCE 5 5'-ATGAAGGTAGGATTGTTGGTA-3' 6 5'-AGTCTTGGTATAATTGTGATGC-3' The mvention also includes primers of the formula X-(R 1 ) m -(R 2 )-(R 3 ) n -Y wherein, at the 5' end of the molecule, X is hydrogen, and at the 3' end of the molecule, Y is hydrogen or a metal. Ri and R3 is any nucleic acid residue, m is an mteger between 1 and 20 or zero , n is an mteger between 1 and 20 or zero, and R 2 is a primer sequence of the mvention, particularly a primer sequence selected from Table 2 In the polynucleotide formula above R is onented so that its 5' end residue is at the left, bound to Ri and its 3' end residue is at the ngh bound to R3 Any stretch of nucleic acid residues denoted by either R group, where m and/or n is greater than 1, may be either a heteropolymer or a homopolymer, preferably a heteropolymer bemg complementary to a region of a polynucleotide of Table 1 In a preferred embodiment m and/or n is an mteger between 1 and 10. The mvention further provides these primers with 1. 2. 3 or 4 nucleotides removed from the 5' and/or the 3' end These primers may be used for, among other things, amplifying nbG DNA isolated from a sample denved from an individual The primers may be used to amplify the gene isolated from an infected individual such that the gene may then be subject to vanous techmques for elucidation of the DNA sequence In tins way. mutations in the DNA sequence may be detected and used to diagnose infection and to serotype and/or classify the infectious agent The mvention further provides a process for diagnosmg. disease, preferably bactenal infections, more preferably infections by Staphylococcus aureus. comprising determining from a sample derived from an individual a mcreased level of expression of polynucleotide having a sequence of Table 1 [SEQ ID NO 1 or 3] Increased or decreased expression of nbG polynucleotide can be measured using any on of the methods well known in the art for the quantation of polynucleotides. such as. for example, amplification. PCR, RT-PCR, RNase protection. Northern blotting and other hybridization methods In addition, a diagnostic assay in accordance w th the mvention for detectmg over- expression of nbG protem compared to normal control tissue samples may be used to detect the presence of an infection, for example Assay techniques that can be used to determme levels of a nbG protein, m a sample denved from a host are well-known to those of skill m the art Such assay methods mclude radiormmunoassays. competitive-binding assays. Western Blot analysis and ELISA assays Antibodies The polypeptides of the mvention or vanants thereof, or cells expressing them can be used as an lmmunogen to produce antibodies lmmunospecific for such polypeptides "Antibodies" as used herem mcludes monoclonal and polyclonal antibodies, chimenc. smgle cham. simianized antibodies and humanized antibodies, as well as Fab fragments, including the products of an Fab immunolglobuhn expression library Antibodies generated against the polypeptides of the mvention can be obtained by administering the polypeptides or epitope-beanng fragments, analogues or cells to an animal, preferably a nonhuman, usmg routme protocols For preparation of monoclonal antibodies, any techmque known m the art that provides antibodies produced by contmuous cell lme cultures can be used Examples mclude vanous techmques, such as those m Kohler. G and Milstein. C . Nature 256 495-497 (1975), Kozbor et al . Immunology Today 4 72 (1983), Cole et al , pg 77-96 m MONOCLONAL ANTIBODIES AND CANCER THERAPY, Alan R Liss, Inc (1985) Techmques for the production of smgle cham antibodies (U S Patent No 4,946.778) can be adapted to produce smgle cham antibodies to polypeptides of this mvention Also, transgemc mice, or other organisms such as other mammals, may be used to express humanized antibodies Alternatively phage display technologv may be utilized to select antibod} genes with bmdmg activities towards the polypeptide either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessmg anti-nbG or from naive libraries (McCafferty. J et al , (1990), Nature 348, 552-554. Marks. J et al , (1992) Biotechnology 10, 779-783) The affinity of these antibodies can also be improved by chain shuffling (Clackson. T et al , (1991) Nature 352, 624-628) If two antigen bmdmg domams are present each domain may be directed against a different epitope - termed 'bispecific' antibodies The above-descnbed antibodies may be employed to isolate or to identify clones expressmg the polypeptides to punfy the polypeptides by affinity Thus, among others, antibodies against nbG- polypeptide may be employed to treat infections, particularly bactenal infections Polypeptide variants mclude antigenically, epitopically or lmmunologically equivalent variants that form a particular aspect of this invention The term "antigenically equivalent derivative" as used herein encompasses a polypeptide or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protem or polypeptide according to the invention, interfere with the immediate physical interaction between pathogen and mammalian host The term "immunologically equivalent derivative" as used herem encompasses a peptide or its equivalent which when used m a suitable formulation to raise antibodies m a vertebrate, the antibodies act to interfere with the immediate physical mteraction between pathogen and mammalian host The polypeptide. such as an antigenically or immunologically equivalent derivative or a fusion protem thereof is used as an antigen to immunize a mouse or other ammal such as a rat or chicken The fusion protem may provide stability to the polypeptide The antigen may be associated, for example by conjugation, with an immunogemc carrier protein for example bovme serum albumin (BSA) or keyhole limpet haemocvanm (KLH) Alternatively a multiple antigemc peptide comprising multiple copies of the protein or polypeptide. or an antigenically or immunologically equivalent polypeptide thereof may be sufficiently antigemc to improve lmmunogenicity so as to obviate the use of a carrier Preferably, the antibody or variant thereof is modified to make it less immunogemc m the mdividual For example, if the individual is human the antibody may most preferably be "humanized", where the comphmentaπty determining regιon(s) of the hybπdoma-deπved antibody has been transplanted mto a human monoclonal antibody . for example as described in Jones. P et al (1986). Nature 321. 522-525 or Tempest et al . (1991) Biotechnology 9, 266-273 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA mto muscles (Wolff et al . Hum Mol Genet 1992, 1 363. Manthorpe et al . Hum Gene Ther 1963 4. 419). deliver} of DNA complexed with specific protein carriers (Wu et al . J Biol Chem 1989 264.16985). coprecipitation of DNA with calcium phosphate (Benvemsty & Reshef. PNAS USA. 1986 83.9551). encapsulation of DNA in various forms of hposomes (Kaneda et al , Science 1989 243.375). particle bombardment (Tang et al , Nature 1992 356 152, Eisenbraun et al DNA Cell Biol 1993, 12 791) and in vivo infection usmg cloned retroviral vectors (Seeger et al . PNAS USA 1984 81,5849) Antagonists .and agonists - assays and molecules Polypeptides of the mvention may also be used to assess the bmdmg of small molecule substrates and gands m. for example, cells, cell-free preparations, chemical hbranes, and natural product mixtures These substrates and hgands may be natural substrates and hgands or may be structural or functional mimetics See, e g , Coligan et al , Current Protocols in Immunology 1(2) Chapter 5 (1991) The mvention also provides a method of screening compounds to identify those which enhance (agomst) or block (antagonist) the action of nbG polypeptides or polynucleotides, particularly those compounds that are bactenostatic and/or bactenocidal The method of screening may involve high-throughput techmques For example, to screen for agonists or antagoists. a synthetic reaction mix. a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, compnsmg nbG polypeptide and a labeled substrate or hgand of such polypeptide is mcubated m the absence or the presence of a candidate molecule that may be a nbG agomst or antagomst The ability of the candidate molecule to agonize or antagonize the nbG polypeptide is reflected in decreased bmdmg of the labeled hgand or decreased production of product from such substrate Molecules that bmd gratuitously, i e , without mducmg the effects of nbG polypeptide are most likely to be good .antagonists Molecules that bmd well and mcrease the rate of product production from substrate are agonists Detection of the rate or level of production of product from substrate may be enhanced by usmg a reporter system Reporter systems that may be useful m this regard mclude but are not limited to colonmetnc labeled substrate converted mto product, a reporter gene that is responsive to changes m nbG polynucleotide or polypeptide activity, and bmdmg assays known m the art Another example of an assay for nbG antagonists is a competitive assay that combmes nbG and a potential antagomst with nbG-bmdmg molecules, recombmant nbG bmdmg molecules, natural substrates or hgands, or substrate or hgand mimetics under appropnate conditions for a competitπe inhibition assay RibG can be labeled such as by radioactivity or a colonmetnc compound, such that the number of nbG molecules bound to a bmdmg molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagomst Potential antagonists mclude small organic molecules, peptides, polypeptides and antibodies that bmd to a polynucleotide or polypeptide of the mvention and thereby inhibit or extinguish its activity Potential antagonists also may be small organic molecules, a peptide. a polypeptide such as a closely related protem or antibody that bmds the same sites on a bmdmg molecule, such as a bmdmg molecule, without mducmg nbG-induced activities, thereby preventmg the action of nbG b} excluding nbG from bmdmg Potential antagonists mclude a small molecule that bmds to and occupies the bmdmg site of the polypeptide thereby preventmg bmdmg to cellular binding molecules, such that normal biological activity is prevented Examples of small molecules mclude but are not limited to small organic molecules, peptides or peptide- ke molecules Other potential antagonists mclude antisense molecules (see Okano, J Neurochem 56 560 (1991), OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION, CRC Press. Boca Raton, FL (1988), for a descnption of these molecules) Prefened potential antagonists mclude compounds related to and vanants of nbG Each of the DNA sequences provided herein may be used in the discovery and development of antibacterial compounds The encoded protem, upon expression, can be used as a target for the screening of antibacterial drugs Additionally, the DNA sequences encoding the ammo terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the codmg sequence of interest The mvention also provides the use of the polypeptide. polynucleotide or inhibitor of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection In particular the molecules of the invention may be used m the prevention of adhesion of bacteria, m particular gram positive bacteria, to mammalian extracellular matrix protems on in-dwelling devices or to extracellular matrix protems m wounds, to block nbG protein-mediated mammalian cell invasion by. for example, initiating phosphorylation of mammalian tyrosme kmases (Rosenshine et al . Infect Immun 60 2211 (1992). to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial nbG protems that mediate tissue damage and, to block the normal progression of pathogenesis in infections initiated other than bv the implantation of in-dwelling devices or by other surgical techmques The antagonists and agonists of the mvention may be employed, for instance, to inhibit and treat diseases Hehcobacter pylori (herem pylori) bactena mfect the stomachs of over one-third of the world's population causmg stomach cancer ulcers, and gastntis (International Agency for Research on Cancer (1994) Schistosomes. Liver Flukes and Hehcobacter Pylori (International Agency for Research on Cancer Lyon France, http //www uicc ch/ecp/ecp2904 htm) Moreover, the international Agency for Research on Cancer recently recognized a cause-and- effect relationship between H pylori and gastric adenocarcinoma classifying the bacterium as a Group I (definite) carcinogen Preferred antimicrobial compounds of the invention (agomsts and antagonists of nbG) found usmg screens provided by the invention, particularly broad- spectrum antibiotics, should be useful m the treatment ofH pylori infection Such treatment should decrease the advent of H pylori -induced cancers, such as gastrointestinal carcmoma Such treatment should also cure gastric ulcers and gastritis Vaccines Another aspect of the mvention relates to a method for mducmg an immunological response m an individual, particularly a mammal which comprises inoculating the mdividual with nbG, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said mdividual from infection, particularly bacterial infection and most particularly Staphylococcus aureus infection Also provided are methods whereby such immunological response slows bacterial replication Yet another aspect of the invention relates to a method of inducing immunological response m an individual which comprises delivering to such mdividual a nucleic acid vector to direct expression of nbG. or a fragment or a vanant thereof, for expressing nbG, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as. to produce antibody and or T cell immune response, mcludmg. for example, cytokine-producmg T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established withm the individual or not One way of administering the gene is by acceleratmg it into the desired cells as a coating on particles or otherwise Such nucleic acid vector may comprise DNA. RNA, a modified nucleic acid, or a DNA/RNA hybrid A further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, mduces an immunological response in such individual to a nbG or protein coded therefrom, wherein the composition comprises a recombmant nbG or protem coded therefrom compnsmg DNA which codes for and expresses an antigen of said nbG or protein coded therefrom The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells A nbG polypeptide or a fragment thereof may be fused with co-protein which ma\ not by itself produce antibodies, but is capable of stabilizing the first protein and producmg a fused protem which will have immunogemc and protective properties Thus fused recombmant protem. preferably further comprises an antigemc co-protem. such as hpoprotem D from Hemophύus influenzae, Glutathione-S-transferase (GST) or beta-galactosidase. relatively large co-protems which solubihze the protein and facilitate production and purification thereof Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system The co-protem may be attached to either the ammo or carboxy terminus of the first protem Provided by this invention are compositions, particularly vaccme compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y et al Science 273 352 (1996) Also, provided by this mvention are methods using the described polynucleotide or particular fragments thereof which have been shown to encode non-variable regions of bacterial cell surface protems m DNA constructs used in such genetic immunization experiments in animal models of infection with Staphylococcus aureus will be particularh useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successful!} resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly Staphylococcus aureus infection, in mammals, particularh humans The polypeptide may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue Examples of tissue damage mclude wounds m skm or connective tissue caused, e g . by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mamman glands, urethra or vagina The invention also includes a vaccine formulation which comprises an immunogemc recombmant protein of the invention together with a suitable carrier Since the protem may be broken down in the stomach, it is preferably administered parenterally, mcludmg, for example, administration that is subcutaneous, intramuscular, intravenous, or mtradermal Formulations suitable for parenteral administration mclude aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants. buffers, bactenostats and solutes which render the formulation msotonic with the bodily fluid, preferably the blood, of the mdividual. and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents The formulations may be presented in unit-dose or multi-dose contamers, for example, sealed ampules and vials and may be stored m a freeze-dned condition requiring only the addition of the sterile liquid earner immediately prior to use The vaccine formulation may also mclude adjuvant systems for enhancing the immunogemcity of the formulation, such as oil-in water systems and other systems known m the art The dosage will depend on the specific activity of the vaccine and can be readily determined by routine expenmentation While the invention has been described with reference to certain nbG protem. it is to be understood that this covers fragments of the naturally occurring protem and similar protems with additions, deletions or substitutions which do not substantially affect the rmmunogenic properties of the recombmant protem Compositions, kits and administration The mvention .also relates to compositions compnsmg the polynucleotide or the polypeptides discussed above or their agonists or antagonists The polypeptides of the mvention may be employed in combination with a non-stenle or stenle earner or earners for use with cells, tissues or organisms, such as a pharmaceutical earner suitable for admimstration to a subject Such compositions compnse, for instance, a media additive or a therapeutically effective amount of a polypeptide of the mvention and a pharmaceutically acceptable earner or excipient Such earners may mclude. but are not limited to. saline, buffered saline, dextrose, water, glycerol. ethanol and combinations thereof The formulation should suit the mode of admimstration The mvention further relates to diagnostic and pharmaceutical packs and kits compnsmg one or more contamers filled with one or more of the ingredients of the aforementioned compositions of the mvention Polypeptides and other compounds of the mvention ma} be employed alone or m conjunction with other compounds, such as therapeutic compounds The pharmaceutical compositions may be administered m any effective, convenient manner mcludmg. for instance, admimstration by topical, oral, anal, vaginal, mtravenous. mtrapentoneal, intramuscular, subcutaneous, rntranasal or mtradermal routes among others In therapy or as a prophylactic, the active agent may be administered to an individual as an mjectable composition, for example as a sterile aqueous dispersion, preferably lsotomc Alternatively the composition may be formulated for topical application for example m the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash impregnated dressings and sutures and aerosols, and may contain appropnate conventional additives, mcludmg. for example, preservatπes. solvents to assist drug penetration, and emollients m ointments and creams Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions Such carriers may constitute from about 1% to about 98% by weight of the formulation, more usually they will constitute up to about 80% by weight of the formulation For admimstration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0 01 mga/kg to 10 mg.kg, typically around 1 mg/Tcg The physician m any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual The above dosages are exemplary of the average case There can. of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention In-dwellmg devices mclude surgical implants, prosthetic devices and catheters, I e , devices that are mtroduced to the body of an individual and remain m position for an extended tune Such devices mclude, for example, artificial joints, heart valves, pacemakers, vascular grafts, vascular catheters, cerebrospinal fluid shunts, urinary catheters, contmuous ambulator}' pentoneal dialysis (CAPD) catheters The composition of the invention may be administered by injection to achieve a systemic effect agamst relevant bacteria shortly before insertion of an m-dwelhng device Treatment may be continued after surgery during the m-body time of the device In addition, the composition could also be used to broaden peπoperative cover for any surgical techmque to prevent bacterial wound infections, especially Staphylococcus aureus wound infections Many orthopaedic surgeons consider that humans with prosthetic joints should be considered for antibiotic prophylaxis before dental treatment that could produce a bacteremia Late deep infection is a serious complication sometimes leadmg to loss of the prosthetic jomt and is accompanied by significant morbidity and mortality It may therefore be possible to extend the use of the active agent as a replacement for prophylactic antibiotics m this situation In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix protems exposed m wound tissue and for prophylactic use in dental treatment as an alternative to. or in conjunction with, antibiotic prophylaxis Alternatively, the composition of the invention may be used to bathe an indwelling device immediately before insertion The active agent will preferably be present at a concentration of lμg/ml to lOmg/ml for bathing of wounds or indwelling devices A vaccme composition is conveniently in mjectable form Conventional adjuvants may be employed to enhance the immune response A suitable unit dose for vaccmation is 0 5-5 microgram kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks With the indicated dose range, no adverse toxicological effects will be observed with the compounds of the invention which would preclude their administration to suitable individuals Each reference disclosed herein is incorporated by reference herem in its entiretv Any patent application to which this application claims priority is also incorporated by reference herein in its entirety GLOSSARY The following definitions are provided to facilitate understanding of certain terms used frequently herem "Dιsease(s)" means and disease caused by or related to infection by a bactena. mcludmg disease, such as, infections of the upper respiratory tract (e g , otitis media, bactenal tracheitis. acute epiglottitis. thyroiditis). lower respiratory (e g . empyema. lung abscess), cardiac (e g . infective endocarditis), gastrointestinal (e g . secretory dianhoea. splenic absces. retropentoneal abscess). CNS (e g . cerebral abscess), eve (e g , blephantis. conjunctivitis, keratitis, endophthalmitis, preseptal and orbital cellulitis, darcryocystitis), kidney and unnary tract (e g . epididymitis. mtrarenal and pennephnc absces. toxic shock syndrome), skin (e g . impetigo, folhcuhtis. cutaneous abscesses. cellulitis, wound infection, bactenal myositis) bone and jomt (e g . septic arthntis. osteomyelitis) "Host cell" is a cell which has been transformed or transfected. or is capable of transformation or transfection by an exogenous polynucleotide sequence "Identity." as known m the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences In the art. "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be. as determined by the match betw een strmgs of such sequences "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those descnbed in (Computational Molecular Biology, Lesk, A M . ed . Oxford University Press. New York. 1988 Biocomputing Informatics and Genome Projects. Smith. D W . ed . Academic Press, New York. 1993. Computer Analysis of Sequence Data. Part I, Griffin, A M , and Griffin, H G . eds , Humana Press. New Jersey. 1994, Sequence Analysis in Molecular Biology, von Hemje. G , Academic Press, 1987. and Sequence Analysis Primer. Gπbskov. M and Devereux, J , eds , M Stockton Press, New York, 1991, and Caπllo, H . and Lipman, D , SIAM J Applied Math , 48 1073 (1988) Preferred methods to determme identity are designed to give the largest match between the sequences tested Methods to determme identity and similarity are codified m publicly available computer programs Preferred computer program methods to determme identity and similarity between two sequences mclude, but are not limited to. the GCG program package (Devereux. J , et al . Nucleic Acids Research 12(1) 387 (1984)). BLASTP. BLASTN. and FASTA (Atschul, S F et al . J Molec Biol 215 403-410 (1990) The BLAST X program is publicly available from NCBI and other sources (BLAST Manual. Altschul. S . et al , NCBI NLM NIH Bethesda. MD 20894, Altschul. S , et al . J Mol B ol 215 403-410 (1990) As an illustration, by a polynucleotide having a nucleotide sequence haλing at least, for example, 95% "identity" to a reference nucleotide sequence of SEQ ID NO 1 it is intended that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence of SEQ ID NO 1 In other words, to obtain a polynucleotide havmg a nucleotide sequence at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides m the reference sequence may be deleted or substituted with another nucleotide. or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted mto the reference sequence These mutations of the reference sequence may occur at the 5 or 3 terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence Analogousl} , by a polypeptide havmg an ammo acid sequence havmg at least, for example. 95% identity to a reference ammo acid sequence of SEQ ID NO 2 is mtended that the ammo acid sequence of the polypeptide is identical to the reference sequence except that the polypeptide sequence may include up to five ammo acid alterations per each 100 ammo acids of the reference ammo acid of SEQ ID NO 2 In other words, to obtain a polypeptide havmg an ammo acid sequence at least 95% identical to a reference ammo acid sequence, up to 5% of the ammo acid residues in the reference sequence may be deleted or substituted with another ammo acid, or a number of ammo acids up to 5% of the total ammo acid residues m the reference sequence may be inserted mto the reference sequence These alterations of the reference sequence may occur at the ammo or carboxy terminal positions of the reference .ammo acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or m one or more contiguous groups within the reference sequence "Isolated" means altered "by the hand of man" from its natural .state, i e , if it occurs m nature, it has been changed or removed from its ongrnal environment, or both For example, a polynucleotide or a polypeptide naturally present m a living organism is not "isolated.' " but the same polynucleotide or polypeptide separated from the coexisting matenals of its natural state is "isolated", as the term is employed herem Moreover, a polynucleotide or polypeptide that is mtroduced mto an organism by transformation, genetic manipulation or by any other recombmant method is "isolated" even if it is still present m said organism, which organism may be living or nonliving "Polynucleotιde(s)" generally refers to any polynbonucleotide or polydeoxnbonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA "Polynucleotide(s)" mclude, without limitation, smgle- and double-stranded DNA. DNA that is a mixture of smgle- and double- stranded regions or smgle-, double- and tnple-stranded regions, smgle- and double-stranded RNA. and RNA that is mixture of smgle- and double-stranded regions, hybnd molecules compnsmg DNA and RNA that may be single-stranded or. more typically, double-stranded, or tnple-stranded regions, or a mixture of smgle- and double-stranded regions In addition, "polynucleotide" as used herem refers to tnple-stranded regions compnsmg RNA or DNA or both RNA and DNA The strands in such regions may be from the same molecule or from different molecules The regions may mclude all of one or more of the molecules, but more typically involve only a region of some of the molecules One of the molecules of a tnple-hehcal region often is an ohgonucleotide As used herein, the term "polynucleotide(s)" also mcludes DNAs or RNAs as descnbed above that contam one or more modified bases Thus. DNAs or RNAs with backbones modified for stability or for other reasons are "polynucleotide(s)" as that term is mtended herem Moreover, DNAs or RNAs compnsmg unusual bases, such as mosme, or modified bases, such as tntylated bases, to name just examples, are polynucleotides as the term is used herem It will be appreciated that a great vanety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art The term "polynucleotide(s)" as it is employed herem embraces such chemically, enzymatically or metabohcally modified forms of polynucleotides, as well as the chemical forms of DNA and RNA charactenstic of viruses and cells, mcludmg, for example, simple and complex cells "Polynucleotide(s)" also embraces short polynucleotides often referred to as olιgonucleotide(s) "Polypeptide(s)" refers to any peptide or protem compnsmg two or more ammo acids joined to each other by peptide bonds or modified peptide bonds "Polypeptιde(s)" refers to both short chains, commonly referred to as peptides, ohgopeptides and ohgomers and to longer chains generally referred to as proteins Polypeptides may contam ammo acids other than the 20 gene encoded ammo acids "Polypeptide(s)" mclude those modified either by natural processes, such as processmg and other post-translational modifications, but also by chemical modification techmques Such modifications are well descnbed m basic texts and m more detailed monographs, as well as in a voluminous research literature, and they are well known to those of skill m the art It will be appreciated that the same type of modification may be present m the same or varying degree at several sites m a given polypeptide Also, a given polypeptide may contam many types of modifications Modifications can occur anywhere m a polypeptide. mcludmg the peptide backbone, the ammo acid side-chains, and the ammo or carboxyl termini Modifications mclude. for example, acetylation. acylation, ADP-nbosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide denvative. covalent attachment of a hpid or pid denvative. covalent attachment of phosphotidylinositol. cross-linking, cychzation. disulfide bond formation, demethylation. formation of covalent cross-links, formation of cysteme. formation of pyroglutamate. formylation, gamma-carboxylation. glycosylation. GPI anchor formation, hydroxylation. lodination. methylation. mynstoylation. oxidation, proteolytic processmg. phosphorylation, prenylation, racemization, ghcosylation. pid attachment, sulfation, gamma- carboxylation of glutamic acid residues, hydroxylation and ADP-nbosylation, selenoylation, sulfation. transfer-RNA mediated addition of ammo acids to protems, such as argrnylation. and ubiquitination See, for instance. PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed . T E Creighton, W H Freeman and Company. New York (1993) and Wold. F . POaSttranslational Protem Modifications Perspectives and Prospects, pgs 1-12 in POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS B C Johnson. Ed . Academic Press, New York (1983). Serfter et al . Meth Enzymol 182 626-646 (1990) and Rattan et al . Protem Synthesis Posttranslational Modifications and Aging. Ami N Y Acad Sci 663 48- 62 (1992) Polypeptides may be branched or cyclic, with or without branching Cyclic, branched and branched circular polypeptides may result from post-translational natural processes and may be made by entirely synthetic methods, as well 'Nanant(s)" as the term is used herem, is a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide respectively, but retains essential properties A typical vanant of a polynucleotide differs m nucleotide sequence from another, reference polynucleotide Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide Nucleotide changes may result m ammo acid substitutions, additions, deletions, fusions and truncations m the polypeptide encoded by the reference sequence, as discussed below A typical vanant of a polypeptide differs m ammo acid sequence from another, reference polypeptide Generally, differences are limited so that the sequences of the reference polypeptide and the vanant are closely similar overall and, in many regions, identical A vanant and reference polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions m any combination A substituted or inserted ammo acid residue may or may not be one encoded by the genetic code A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allehc variant, or it may be a variant that is not known to occur naturally Non- naturally occurrmg variants of polynucleotides and polypeptides may be made by mutagenesis techmques. by direct synthesis, and by other recombmant methods known to skilled artisans EXAMPLES The examples below are earned out usmg standard techmques. which are well known and routme to those of skill m the art. except where otherwise descnbed m detail The examples are illustrative, but do not limit the mvention Example 1 Strain selection, Library Production .and Sequencing The polynucleotide havmg a DNA sequence given in Table 1 [SEQ ID NO 1 or 3] was obtamed from a library of clones of chromosomal DNA of Staphylococcus aureus in E cob The sequencmg data from two or more clones containing overlapping Staphylococcus aureus DNAs was used to construct the contiguous DNA sequence in SEQ ID NO 1 Libraries may be prepared by routine methods, for example Methods 1 and 2 below Total cellular DNA is isolated from Staphylococcus aureus WCUH 29 according to standard procedures and size-fractionated by either of two methods Method 1 Total cellular DNA is mechanically sheared by passage through a needle m order to size-fractionate according to standard procedures DNA fragments of up to 1 lkbp m size are rendered blunt by treatment with exonuclease and DNA polymerase, and EcoRI linkers added Fragments are ligated mto the vector Lambda ZapII that has been cut with EcoRI, the library packaged by standard procedures and E coh infected with the packaged library The library is amplified by standard procedures Method 2 Total cellular DNA is partially hydrolyzed with a one or a combination of restriction enzymes appropriate to generate a series of fragments for cloning mto library vectors (e g , Rsal, Pall. Alul, Bshl235I), and such fragments are size-fractionated according to standard procedures EcoRI linkers are ligated to the DNA and the fragments then ligated into the vector Lambda ZapII that have been cut with EcoRI. the library packaged by standard procedures, and E coh infected with the packaged library The library is amplified by standard procedures Example 2 ribG Characterization Riboflavin Biosynthesis Operon This ORF is part of an operon which encodes genes ribG. nbB, nbA and nbH Gene nbG starts at nucleotide 1 and ends at nucleotide 1029 Gene nbB starts at nucleotide 1036 and ends at nucleotide 1668 Gene nbA starts at nucleotide 1679 and ends at nucleotide 2860 Gene nbH starts at nucleotide 2873 and ends at nucleotide 3337 The operon sequence belov. ATGGATTATGCGATTCAACTTGCAAATATGGTACAAGGTCAAACAGGTGTTAATCCACCCGTTGGCGCT GTTGTAGTTAATGAAGGTAGGATTGTTGGTATTGGTGCACACTTGAGAAAAGGTGACAAGCATGCGGAG GTTCAAGCACTTGATATGGCACAACAAAATGCTGAAGGTGCGACGATTTATATTACGTTAGAGCCATGT AGTCATTTTGGTTCAACACCACCCTGTGTTAACAAAATTATTGATTGTAAGATAGCAAAAGTAGTATAC GCAACAAAAGACAATTCGTTAGACACACATGGTGATGAGACGTTACGGGCTCACGGTATTGAGGTTGAA TGCGTTGATGATGAACGGGCATCACAATTATACCAAGACTTTTTTAAAGCAAAAGCAAAGCAACTGCCA CAAATTACAGTGAAAGTATCTGCAAGTTTAGATGGTAAACAAGCGAATGATAATGGACAAAGTCAATGG ATTACTAACAAAGAGGTTAAACAAGATGTCTATAAGTTAAGACATCGACACGACGCAGTGTTAACTGGA AGACGTACAGTTGAATTAGATGATCCACAATATACTACACGTATTCAAGATGGAAAAAACCCTATAAAA GTAATATTGTCTAAGTCTGGGAATATTCATTTTAATCAGCAAATTTATCAAGATGAATCAACACCAATT TGGATATATACTGAAAATCCAAATTTAACAAGCAATCAAACACATATTGAAATTATTTACTTGAAGTCT TGTGATTTAACAACAATTCTTCACAATTTATATAAAAGAGGAGTTGGAACTTTGCTAGTCGAGGCAGGT CCAACCACTACTTCAGAATTCTCCATCTATTATATAGATGAATTTATTCTCTATTATGCCCCGAAATTA ATTGGCGGATCTGGAAATTATCAATTTTATCAAACAAATGATGTGATTGAGATACCAGATGCGAACCAA TTTGAAATTGTTCATTCCGAGTTATTAAATCAAAATGTTAAATTAACTTTACGAAAGAAGTGATGATGC ATGTTTACTGGCATCGTTGAAGAAATAGGTGTCGTTAAAAGTGTTCAAATTCGTCAATCAGTCAGGACG ATTGAAATCGAAGCACATAAGATTACGGCAGATATGCATATTGGTGATTCCATCAGTGTTAATGGTGCA TGTTTAACAGTGATTGATTTTGATCAGACATCTTTTACTGTTCAAGTAATTAAAAGCACTGAAAATAAA ACCTATTTAGCAGATGTTAAGCGACAATCAGAAGTAAATTTAGAGCGTGCCATGAGTGGTAACGGTAGG TTTGGTGGACATTTTGTCCTCGGTCATGTAGATGAACTAGGAACAGTTT CAAAAATAAATGAAACAGCCAATGCCAAAATTATTACGATTCAATGTAGCCAACATATTAATAATCAGT TAGTTAAGCAAGGGTCTATTACTGTGGATGGTGTAAGTCTAACGGTATTTGATAAGCATGATAACAGTT TTGACATTCATCTTATTCCAGAAACGAGGCGTTCAACGATTTTATCATCCAAAAAATTAGGAGATAAAG TACATTTAGAAACAGACGTTTTGTTTAAATATGTTGAAAATATTTTAAATAAAGATAAAGACCAATTAT CTGTAGATAAATTAAGAGCATTTGGTTTTTAGGAGGGGTAGCATGCAATTCGATAATATTGACAGTGCT TTAATGGCTTTAAAAAATGGAGAAACAATTATTGTAGTAGATGATGAGAATCGTGAAAATGAAGGTGAT TTAGTAGCGGTTACTGAATGGATGAACGATAATACCATTAATTTTATGGCGAAAGAAGCAAGGGGATTA ATATGCGCACCAGTGTCTAAAGATATTGCACAACGTTTGGATTTGGTACAAATGGTTGATGATAACTCC GACATCTTTGGTACGCAATTTACAGTGAGTATTGATCATGTAGATACAACAACAGGAATTAGTGCTTAT GAACGTACATTGACTGCCAAAAAGCTCATTGATCCTAGTAGTGAAGCTAAAGATTTTAATCGTCCTGGT CATTTATTTCCATTAGTAGCACAAGATAAAGGCGTATTAGCTAGAAATGGACACACAGAAGCGGCTGTT GATTTAGCTAAACTTACTGGTGCCAAGCCCGCTGGTGTCATTTGTGAGATTATGAATGATGACGGCACG ATGGCGAAAGGACAAGATTTACAAAATTTTAAAGAAAAACATCAATTAAAGATGATTACGATTGATGAT TTAATTGAATATCGTAAAAAATTAGAACCAGAAATTGAATTTAAGGCAAAAGTGAAAATGCCTACAGAT TTCGGAACATTTGATATGTATGGTTTTAAAGCGACATACACAGATGAAGAGATAGTTGTACTGACAAAA GGTGCAATTCGACAACATGAAAATGTACGCTTACATTCTGCGTGCCTTACAGGCGATATTTTCCATAGT CAACGTTGTGATTGTGGTGCTCAACTTGAATCGTCTATGAAGTATATCAATGAACATGGTGGCATGATT ATTTATCTACCTCAAGAAGGTCGTGGCATAGGATTGTTAAACAAATTACGCGCATATGAATTAATTGAG CAAGGATATGATACAGTAACTGCAAATTTAGCATTAGGTTTTGATGAAGATTTACGAGATTATCATATT GCTGCACAGATTTTAAAATATTTTAACATCGAACATATCAATTTATTAAGTAATAATCCAAGTAAATTT GAGGGATTAAAACAATATGGCATTGATATTGCAGAAAGAATTGAAGTTATCGTACCAGAAACGGTACAT AATCATGATTATATGGTAACGAAAAAAATAAAAATGGGTCATTTAATATAGGAGGACTTTAACATGAAT TTTGAAGGTAAATTAATTGGAAAAGATTTGAAAGTTGCAATCGTAGTTAGTCGATTTAATGATTTTATC ACTGGAAGATTACTTGAAGGTGCAAAAGATACTTTGATTCGACATGATGTTAATGAAGACAATATTGAT GTAGCATTTGTTCCTGGTGCGTTTGAAATTCCTTTAGTAGCTAAAAAATTAGCCTCATCAGGAAATTAT GATGCAATAATTACATTAGGATGCGTAATTCGCGGTGCTACGTCTCATTATGATTATGTTTGTAATGAA GTGCGAAAGGTGTTTCTAAAGTAAATGATCAAACTAATGTACCAGTCATATTTGGTATTTTAACGACTG AAAGTATTGAACAAGCTGTGGAAAGAGCAGGTACGAAAGCTGGTAATAAAGGTGCCGAAGCAGCAGTAA GTGCAATTGAAATGGCTAATTTATTAAAATCTATAAAAGCATAG

Claims: What is claimed is: 1 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 2 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identify to a polynucleotide encodmg the same mature polypeptide expressed by the nbG gene contained m the Staphylococcus aureus of the deposited stram 3 An isolated polynucleotide compnsmg a polynucleotide encodmg a polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 4 An isolated polynucleotide that is complementary to the polynucleotide of claim 1 5 The polynucleotide of Clami 1 wherem the polynucleotide is DNA or RNA 6 The polynucleotide of Claim 1 compnsmg the nucleic acid sequence set forth m SEQ ID NO 1 7 The polynucleotide of Claim 1 compnsmg nucleotide 1 to the stop codon which begins at nucleotide number 1027 set forth m SEQ ID NO 1 8 The polynucleotide of Claim 1 which encodes a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 2 9 A vector compnsmg the polynucleotide of Claim 1 10 A host cell compnsmg the vector of Claim 9 11 A process for producmg a polypeptide compnsmg expressmg from the host cell of Claim 10 a polypeptide encoded by said DNA 12 A process for producmg a nbG polypeptide or fragment comprising cultuπng a host of claim 10 under conditions sufficient for the production of said polypeptide or fragment 13 A polypeptide compnsmg an ammo acid sequence which is at least 70% identical to the ammo acid sequence of SEQ ID NO 2 14 A polypeptide compnsmg an ammo acid sequence as set forth m SEQ ID NO 2 15 An antibody against the polypeptide of claim 14 16 An antagomst which inhibits the activity or expression of the polypeptide of claim 14 17 A method for the treatment of an mdividual m need of nbG polypeptide compnsmg admmistenng to the mdividual a therapeutically effective amount of the polypeptide of claim 14 18 A method for the treatment of an mdividual havmg need to inhibit nbG polypeptide compnsmg administering to the mdividual a therapeutically effective amount of the antagomst of Claim 14 19 A process for diagnosing a disease related to expression or activity of the polypeptide of claim 14 m an individual compnsmg (a) determining a nucleic acid sequence encodmg said polypeptide. and/or (b) analyzing for the presence or amount of said polypeptide m a sample denved from the mdividual 20 A method for identifying compounds which interact with and inhibit or activate an activity of the polypeptide of claim 14 compnsmg contacting a composition compnsmg the polypeptide with the compound to be screened under conditions to permit mteraction between the compound and the polypeptide to assess the mteraction of a compound, such mteraction bemg associated with a second component capable of providing a detectable signal in response to the mteraction of the polypeptide with the compound. and determining whether the compound mteracts with and activates or inhibits an activity of the polypeptide by detectmg the presence or absence of a signal generated from the mteraction of the compound with the polypeptide 21 A method for inducing an immunological response in a mammal which comprises inoculating the mammal with nbG polypeptide of claim 14. or a fragment or variant thereof, adequate to produce antibody and or T cell immune response to protect said animal from disease 22 A method of mducmg immunological response in a mammal which comprises delivering a nucleic acid vector to direct expression of nbG polypeptide of claim 14. or fragment or a variant thereof, for expressing said nbG polypeptide. or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibody and/ or T cell immune response to protect said animal from disease 23 An isolated polynucleotide compnsmg a polynucleotide havmg at least a 70% identity to a polynucleotide encodmg a polypeptide compnsmg the ammo acid sequence of SEQ ID NO 4 24. An isolated polynucleotide comprising a polynucleotide having at least a 70% identity to the polynucleotide sequence of SEQ ID NO:3.

Inventors: BLACK MICHAEL T, BURNHAM MARTIN K R, FEDON JASON C, HODGSON JOHN E, KNOWLES DAVID J C, LONETTO MICHAEL A, NICHOLAS RICHARD O, PALMER LESLIE M, PRATT JULIE M, REICHARD RAYMOND W, ROSENBERG MARTIN, TRANI CHRISTOPHER M, WARD JUDITH M, WARREN RICHARD L, BLACK, MICHAEL, T., BURNHAM, MARTIN, K., R., FEDON, JASON, C., HODGSON, JOHN, E., KNOWLES, DAVID, J., C., LONETTO, MICHAEL, A., NICHOLAS, RICHARD, O., PALMER, LESLIE, M., PRATT, JULIE, M., REICHARD, RAYMOND, W., ROSENBERG, MARTIN, TRANI, CHRISTOPHER, M., WARD, JUDITH, M., WARREN, RICHARD, L.
Applicants: SMITHKLINE BEECHAM CORP, SMITHKLINE BEECHAM CORPORATION
Application year: 1998
Main classification: A01N43
IPC codes: A61K38, A61K39, A61K48, A61P31, C07K14, C07K16, C12N1, C12N5, C12N9, C12N15, C12Q1, G01N33